Currently, various therapeutic strategies are being explored as a potential means to immunize against metastatic malignant cells or even primary tumours. Using recombinant viral vectors systems or protein-based immunization approaches, we are developing immunotherapeutic strategies against cervical cancer or premalignant cervical disease, as induced by high-risk type human papillomaviruses (HPVs). We previously demonstrated that immunization of mice with recombinant replication-defective Semliki Forest virus (rSFV) encoding a fusion protein of HPV16 E6 and -E7 (SFV-eE6,7) induces strong cytotoxic T-lymphocyte (CTL) activity and eradication of established HPV-transformed tumours. In this study, we compared the antitumour efficacy of SFV-eE6,7 with that of a recombinant adenovirus (rAd) type 5 vector, expressing the same antigen construct (AdeE6,7). Prime-boosting with SFV-eE6,7 resulted in higher precursor CTL frequencies and CTL activity compared to prime-boosting with Ad-eE6,7 and also in murine tumour treatment experiments SFV-eE6,7 was more effective than Ad-eE6,7. To elicit a therapeutic effect with Ad-eE6,7, 100/1000-fold higher doses were needed compared to SFV-eE6,7. In vivo T-cell depletion experiments demonstrated that these differences could not be explained by the induction of a different type of effector cells, since CD8 + T cells were the main effector cells involved in the protection against tumour growth in both rSFV-and rAd-immunized mice. Also comparable amounts of in vivo transgene expression were found upon immunization with rSFV and rAd encoding the reportor gene luciferase. However, antivector responses induced by a single injection with rAd resulted in a more than 3-log decrease in luciferase expression after a second injection of rAd. With rSFV, transgene expression was inhibited by only one to two orders of magnitude in preinjected mice. As an antigen-specific booster immunization strongly increases the level of the CTL response and is essential for efficient induction of immunological memory, it is likely that (part of) the difference in efficacy between rSFV and rAd type 5 can be ascribed to a diminished efficacy of the booster immunization in the case of rAd due to anti-vector antibody responses.
Introduction
We are developing immunotherapeutic strategies against cervical cancer or premalignant cervical disease using replication-defective recombinant viral vector systems [1] [2] [3] [4] [5] or protein-based immunization approaches. 6 Cervical cancer is the second most common type of cancer among women worldwide, and the first malignancy recognized by the World Health Organization to be 100% attributable to infection with a virus, specifically a high-risk type human papillomavirus (HPV). 7, 8 Malignant cell transformation by HPVs involves integration of part of the viral genome into the chromosomal DNA of susceptible cervical epithelial cells. Subsequent constitutive expression of the E6 and E7 early viral genes results in inhibition of the tumour suppressor proteins p53 and pRb, respectively, and thus in a loss of cell-cycle control. 9, 10 Since the sustained expression of E6 and/or E7 is a prerequisite for maintenance of the transformed cellular phenotype, these proteins in fact represent tumour-specific antigens and thus are potentially suitable targets for immunotherapeutic strategies against cervical cancer or premalignant cervical disease. 11 Therapeutic immunization against tumour cells requires the induction of cytotoxic T lymphocytes (CTLs) that can specifically recognize and lyse tumour cells. For the differentiation, expansion and memory induction of tumour-specific CTLs, T-helper cells (Th cells) and properly activated antigen-presenting cells, dendritic cells (DCs) in particular, are essential.
Preclinical evaluation of a recombinant replicationdefective Semliki Forest virus (SFV) vector, expressing a fusion protein of HPV type 16 E6 and -E7, has demonstrated the ability of this system to induce strong E6/E7-specific CTL activity in normal 1, 3 and immunetolerant E6/E7 transgenic 4 mice and to eradicate pre-established, subcutaneously implanted, HPV-transformed tumours in a murine tumour model. 2 However, despite the apparent potential of this approach, clinical evaluation of an SFV-based therapeutic immunization strategy is hampered by the fact that there is no prior human clinical experience with this vector system which would facilitate regulatory procedures.
A recombinant viral vector that has been evaluated extensively in human clinical studies is the adenovirus (Ad) system. [12] [13] [14] Like recombinant SFV-based vector systems, recombinant Ads (rAds) are attractive vaccine candidates, harbouring several advantageous features. rAds are easy to construct and propagate, they are replication-incompetent and can transduce a wide range of dividing and non-dividing cells, including antigenpresenting cells, and give high levels of transgene expression. 15, 16 The only major limitation in the clinical application of rAd is the prevalence of pre-existing or inducible antiviral immunity. 17, 18 In this study, with the goal of rapidly bringing a therapeutic genetic immunization approach against (pre)malignant cervical disease to the clinic, we evaluated a recombinant replication-defective Ad vector expressing HPV16 E6/E7 antigen, in our murine model system and compared its efficacy with that of SFVmediated immunization in terms of induction of CTL activity and antitumour responses.
Results
Efficacy of Ad-eE6,7 compared to SFV-eE6,7 with respect to the induction of HPV-specific CTLs
To compare the efficacies of rAd and recombinant replication-defective SFV (rSFV) as vectors for the induction of antitumour activity, rAd and rSFV were generated encoding the same HPV16 E6,7 construct. This construct encodes the E6 and E7 protein of HPV16 as a fusion protein. 1 Next, Ad-eE6,7 and SFV-eE6,7 particles were compared in immunization and in vivo tumour treatment experiments. Precursor CTL (pCTL) frequencies and CTL activity were determined 1 week after the last (booster) immunization by the direct staining of spleen cells with major histocompatibility complex (MHC) class I tetramers refolded with HPV16 E7 49-57 peptide and a standard bulk CTL assay, respectively.
As shown in Figure 1 , two intramuscular (i.m.) or intravenous (i.v.) immunizations with 5 Â 10 6 SFV-eE6,7 resulted in a significantly higher CTL activity than two i.m. immunizations with a 100-fold higher dose of AdeE6,7. As a control, mice were injected twice with a twofold higher dose of rAd encoding an irrelevant gene (Ad-Luc) or with SFV-LacZ (data not shown), which did not evoke any CTL activity. Similar levels of specific lysis were obtained using C3 or 13-2 cells; only the results obtained with the C3 cells are shown.
In a dose-response experiment, the difference in CTL activity seen between Ad-eE6,7 and SFV-eE6,7 was also reflected in the frequencies and the proliferative capacity of pCTLs induced (Figure 2 ). Prime-boost immunizations with as few as 10 4 SFV-eE6,7 particles induced considerable levels of HPV-specific CTL precursors (Figure 2a ) that upon in vitro re-stimulation readily expanded (Figure 2b) . The very low level of pCTLs induced upon immunization with 10 7 Ad-eE6,7 could not be expanded significantly above background levels by the 7-day restimulation protocol. Immunizations with 10 8 and 10 9 did result in detectable levels of pCTLs that expanded upon re-stimulation. Yet, while in this experiment pCTLs isolated from SFV-immunized mice expanded to approximately 30-60% of the CD8 + , pCTLs isolated from Ad-immunized mice expanded to approximately 10% of the CD8 + T-cell population (Figure 2b ). To illustrate these responses Figure 2c shows typical flow cytometry data of Figure 1 Efficacy of Ad-eE6,7 compared to SFV-eE6,7 with respect to the induction of HPV-specific CTLs. CTL activity induced upon immunization with SFV-eE6,7 particles versus Ad-eE6,7 particles. Mice were immunized and boosted with 5 Â 10 6 SFV-eE6,7 intravenously (n ¼ 7, closed diamonds), with 5 Â 10 6 SFV-eE6,7 intramuscularly (n ¼ 7, open diamonds), 5 Â 10 8 Ad-eE6,7 intramuscularly (n ¼ 7, closed squares) or with 1 Â 10 9 Ad-luc intramuscularly (n ¼ 3, closed triangles) or PBS (n ¼ 3, open circles) as controls. CTL activity was determined 1 week after the booster immunization. After 7 days of in vitro re-stimulation, the resulting effector cells were tested for cytolytic activity against C3 target cells in triplicate well assay. The levels of cytolysis at different effector-totarget ratios are shown. Control immunizations with 5 Â 10 6 SFVLacZ did not induce CTL activity (data not shown). 1, 3 Shown are the results of a typical experiment repeated three times. Both the i.v. and i.m. SFV-eE6,7 immunization groups and i.m. Ad-eE6,7 immunization group were significantly different compared to the PBS control group (Po0.03). Both routes of SFV-eE6,7 immunizations were significantly different compared to Ad-eE6,7 (P ¼ 0.006). Ad, adenovirus; HPV, high-risk type human papillomavirus; SFV, Semliki Forest virus; CTL, cytotoxic T lymphocyte; i.m, intramuscular; i.v., intravenous.
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A Riezebos-Brilman et al spleen cells either stained directly upon isolation or after a 7-day in vitro re-stimulation of mice immunized with 10 9 Ad-eE6,7, 10 5 SFV-eE6,7 or buffer. For SFV immunizations, we previously demonstrated that the route of immunization determines to a large extent the outcome of the immune response evoked, i.v. and i.m immunizations being significantly more efficient than intraperitoneal (i.p.) or subcutaneous (s.c.) immunization. 3 To determine the optimal route of injection for adenoviral immunization, 5 Â 10 8 Ad-eE6,7 particles were administered via different routes (i.m., i.p. or s.c), twice with a 2-week interval. As intravenous injection of rAd is hepatotoxic, Ad-eE6,7 was not administered via this route. 19, 20 Only upon i.m. immunization low but detectable CTL activity was induced; s.c. and i.p. immunization did not induce detectable CTL activity (Figure 3 ). Although the bulk CTL analysis did not reveal any CTL activity, tetramer analysis demonstrated low but detectable pCTL frequencies by s.c. immunization. Upon i.p. immunization pCTLs frequencies, if induced, were below detection limit (data not shown). Immunotherapeutic efficacy of recombinant SFV and adenovirus vector systems A Riezebos-Brilman et al Therapeutic efficacy of immunization with Ad-eE6,7 versus SFV-eE6,7
We next determined whether the observed difference in CTL activity induced by both vectors is also reflected in the therapeutic efficacy in eradicating established tumours. In the following antitumour experiments, AdeE6,7 was compared to intravenously injected SFV-eE6,7 as our gold standard. We previously demonstrated that i.m. and i.v. SFV-eE6,7 immunizations resulted in similar levels of pCTL frequencies, CTL activity (also see Figure  1 ) and antitumour responses. 3 Mice were inoculated subcutaneously in the neck with 2 Â 10 4 TC-1 cells and subsequently immunized and boosted twice with increasing doses of Ad-eE6,7 or SFV-eE6,7 particles. All control mice, either injected intramuscularly with buffer or with Ad-luc, developed tumours within 14 days after tumour inoculation ( Table 1) . As shown in Table 1 , 60% of the mice immunized and boosted with 1 Â 10 9 AdeE6,7 intramuscularly on days 7, 14 and 21 after tumour inoculation eradicated the tumour and subsequently remained tumour free for the next 2 months. Upon immunization with 1 Â 10 8 and 1 Â 10 7 Ad-eE6,7, 40 and 20% of the mice, respectively, cleared the tumour and remained tumour free. In contrast, all mice immunized and boosted with 1 Â 10 6 SFV-eE6,7 intravenously on days 7, 14 and 21 after tumour inoculation eradicated the tumour. When immunizations were initiated as late as 14 days after the tumour inoculation, all mice treated with 1 Â 10 9 Ad-eE6,7 developed a tumour, whereas still 40% of the mice treated with 1 Â 10 6 SFV-eE6,7 eradicated the tumour and remained tumour free.
Thus, the observed difference in CTL induction is also reflected in the therapeutic effect, that is SFV-eE6,7 immunization has a significantly better therapeutic effect compared to Ad-eE6,7 immunization. Even with a 1000-fold lower dose of SFV-eE6,7 all mice efficiently eradicated the tumour compared to 60% in the group treated with Ad-eE6,7.
Effect of CD4
+ and/or CD8 + T-cell depletion on the antitumour effects of Ad-eE6,7 and SFV-eE6,7
Although not as effective as SFV-eE6,7, immunization of mice with Ad-eE6,7 did generate antitumour responses. Considering the low levels of antigen-specific CTLs induced upon Ad-eE6,7 immunizations, we investigated whether different lymphocyte subsets might be involved in the antitumour effect evoked by rAd and rSFV. To determine the actual effector cells involved in the antitumour effect seen in mice immunized with AdeE6,7 or SFV-eE6,7, we in vivo depleted T-cell subsets using monoclonal antibodies (mAbs). Mice were immunized and subsequently depleted of CD4 + T cells, CD8
+ T cells or both T-cell populations. Next, the mice were inoculated subcutaneously in the neck with 2 Â 10 4 TC-1 cells. During the experiment, the depletion of the T-cell subsets was maintained by weekly injections with antibodies. As shown in Figure 4a , all mice in the control group developed tumours within 14 days after tumour inoculation. In the group of immune-competent mice, 7 of 7 mice receiving 5 Â 10 6 SFV-eE6,7 were protected from tumour outgrowth ( + T cells may play a minor role in the antitumour response in mice immunized with rSFV as tumour growth was slightly delayed in the group only depleted of CD8 + T cells compared to the phosphate-buffered saline (PBS) control group and the group depleted of both T-cell populations.
Luciferase activity induced upon i.m. injection with Ad-luc and SFV-luc
Since immunization with Ad-eE6,7 results in a significantly lower CTL and antitumour activity compared to SFV-eE6,7 immunizations, we investigated if the amount of transgene product expressed in vivo could possibly explain this difference. Therefore, we performed an in vivo transfection experiment with Ad-luc and SFV-luc. Since the time point of maximal expression of the transgene product after rSFV and rAd injection differs, we determined the expression level of luciferase at 24 h after SFV-luc injection and at 48 h for Ad-luc. 21, 22 As shown in Figure 5 , comparable levels of luciferase activity were measured in the muscles of the mice injected with 1 Â 10 6 SFV-luc and 5 Â 10 8 Ad-luc. In the above immunization studies, all mice received a booster immunization. It is known that rAd elicits a strong anti-vector response. Anti-vector responses elicited by rSFV are not well documented. We therefore Mice were immunized and boosted twice with SFV-eE6,7 intravenously, Ad-eE6,7, Ad-luc or buffer intramuscularly after tumour inoculation according to the schemes and dosages as indicated. *Significant different (Po0.01) compared to buffer control group using w 2 analysis.
Immunotherapeutic efficacy of recombinant SFV and adenovirus vector systems A Riezebos-Brilman et al determined the level of recombinant protein produced by a second injection injection with rAd or rSFV. To this end, mice were preinjected intramuscularly with rAd or rSFV expressing b-galactosidase (that is, Ad-lacZ and SFV-lacZ) 2 weeks before injection of Ad-luc or SFV-luc, respectively. Preinjection of mice with Ad-lacZ resulted in a more than 3-log decrease in luciferase expression compared to naive Ad-luc-injected mice. In mice injected with SFV-lacZ first and with SFV-luc next, luciferase activity was decreased by 1-2 orders of magnitude compared to SFV-mediated luciferase expression in SFV-naive mice ( Figure 5 ).
Single versus prime-boost immunizations with Ad-eE6,7 and SFV-eE6,7
To analyse the efficacy of a booster immunization of AdeE6,7 and SFV-eE6,7, mice were either injected with 5 Â 10 8 Ad-eE6,7 and 'boosted' 2 weeks later with buffer or the other way around, or mice were primed and boosted with 5 Â 10 8 Ad-eE6,7. Other groups of mice were similarly immunized with SFV-eE6,7. While the booster immunization did not significantly increase pCTL frequencies of single-Ad-eE6,7-immunized mice, the pCTL frequency of single-SFV-eE6,7-immunized mice increased significantly from approximately 0.5-1.5% ( Figure 6 ).
Discussion
In this study, we compared the efficacies of rSFV and rAd as vectors for the induction of cellular and antitumour responses against HPV-induced cervical cancer. We previously demonstrated that immunizations with rSFV-eE6,7 result in very potent CTL and antitumour responses in murine animal models. [1] [2] [3] [4] However, rSFV has not yet been evaluated in humans hampering a facile introduction of SFV-based immunotherapeutic strategies into the clinic. On the other hand, rAd vectors have already been used in numerous clinical studies against a variety of infectious diseases and tumours. [12] [13] [14] 16 Thus, rAd immunizations could potentially be a good alternative for the immunotherapy of cervical cancer. In this study, we compared the efficacies of both vector systems.
Here, we demonstrate that immunization with SFV expressing the HPV E6 and -E7 antigens results in twofold higher E7-specific CTL precursor frequencies compared to immunizations with 100-fold more infectious particles of an adenoviral vector encoding the same antigens. The therapeutic efficacy of both vectors in eradicating established tumours was studied in a murine HPV-tumour model. Despite the low levels of CTL induced upon immunization with Ad-eE6,7, up to 60% of the mice eradicated the tumour. In line with our previous studies, all mice immunized with a 1000-fold Immunotherapeutic 6 ) of SFV-eE6,7 eradicated the tumours.
To explore the possible mechanisms that might explain the difference in efficacy between both vectors we determined (i) the role of CD4 + and CD8 + T cells in the antitumour responses elicited, (ii) the protein expression levels of both vectors and (iii) the influence of possible anti-vector responses on booster injections. The role of CD4 + and CD8 + T lymphocytes in the antitumour response was investigated by determining the efficacy of the immunizations in the presence or absence of these Tcell subsets. Mice were immunized and subsequently depleted of their CD4 + T cells, CD8 + T cells or both T-cell populations using antibodies. Subsequently, the mice were challenged subcutaneously with tumour cells. Upon depletion of CD8 + T cells in both the rSFV-and the rAd-immunized group, mice were no longer protected against tumour growth. Notably, in the rSFVimmunized group depletion of only the CD8 + T cells resulted in a slight delay of tumour growth of 3-5 days compared to the rSFV-immunized group depleted of both T-cell populations and the PBS-immunized group, suggesting that also CD4 + T cells may have some antitumour effect. However, this delay, which was not observed in the rAd-treated group, was not significant, and therefore most likely does not explain the difference in efficacy between both vectors. Depletion of only the CD4 + T cells did not affect the antitumour responses elicited with both vector systems. Thus, CD8 + T cells seem to be the main effector cells involved in the protection against tumour growth elicited both by rSFV and rAd. [23] [24] [25] As the lymphocyte subsets cannot explain the difference in efficacy, we next determined the amount of antigen expressed in vivo with rSFV and rAd. For this, the expression of luciferase after i.m. injection of Ad-luc and SFV-luc was determined. It should be noted that we previously demonstrated that i.m. and i.v. SFV-eE6,7 immunizations resulted in similar levels of pCTL frequencies, CTL activity and antitumour responses. 3 As the time point of maximal expression of the transgene product after rSFV and rAd injection differs, luciferase expression level was determined at 24 h after SFV-luc and at 48 h after Ad-luc injection. 21, 22 Intramuscular injection of 1 Â 10 6 SFV-luc and 5 Â 10 8 Ad-luc resulted in comparable levels of luciferase in the muscles of the mice at these given time points. It should however be noted that 2-3 days after SFV infection, cells die through apoptosis, and hence transgene expression stops. 21 In contrast, transgene expression in cells infected with rAd may lasts for several weeks. 22 Thus the total amount of transgene produced by rAd is much higher than that produced with rSFV. One could therefore hypothesize that, as a consequence of this long-term production of antigen, immunization with rAd should be more efficient than rSFV. Yet, despite the short expression of antigen induced with rSFV compared to rAd, the immune responses elicited with rSFV immunization are more effective in eradicating tumour cells. Although not determined in this study one could also envision that the rate of degradation of the E6,7 fusion protein may differ depending on the expression system.
Pre-existing anti-vector immunity represents a major problem in the development of vector-based vaccines. Anti-Ad serotype 5 (Ad5) immunity has already been Figure 6 Single versus prime-boost immunizations with Ad-eE6,7 and SFV-eE6,7. Mice were either injected with 5 Â 10 8 Ad-eE6,7 followed by an injection with buffer 2 weeks later (n ¼ 3), a second group of mice was first injected with buffer followed by 5 Â 10 8 Ad-eE6,7 (n ¼ 3), and a third group of mice was injected twice with a 2-week interval with 5 Â 10 8 Ad-eE6,7 (n ¼ 7). Other groups of mice were similarly immunized intramuscularly with SFV-eE6,7. One week after the injection, spleen cells were isolated and pCTL frequencies were determined with a FITC-labelled mAb against CD8 + and a PE-labelled HPV16 E7 49-57 -specific MHC class I tetramer and analysed by flow cytometry. Data represent percentages of E7 49-57 tetramer-positive CD8 + cells of individual mice of a typical experiment repeated twice. Precursor frequencies in groups of mice immunized and boosted with SFV-eE6,7 or with Ad-eE6,7 were significantly different from the buffer control group (P ¼ 0.017). All other groups were not significantly different from the PBS control group. Ad, adenovirus; HPV, high-risk type human papillomavirus; i.m., intramuscular; MHC, major histocompatibility complex; mAb, monoclonal antibody; SFV, Semliki Forest virus; PE, phycoerythin; PBS, phosphate-buffered saline; pCTL, precursor cytotoxic T lymphocyte. 
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shown to substantially suppress the immunogenicity of rAd5 vector-based vaccines. [26] [27] [28] Neutralizing antibodies reduce transfection of the adenoviral vectors by cells, and thus expression of the transgene product, which in turn impacts the resulting transgene productspecific immune response. In this study, we confirm these studies by demonstrating that anti-vector responses elicited by prior injections with immuneactivating doses of our rAd reduce transgene (luciferase) expression of a subsequent injection with rAd more than 3 log. Anti-vector responses elicited by rSFV are not very well documented. Berglund et al. 29 showed that upon immunization with SFV, the immune responses against SFV did not disable boost responses by subsequent immunizations with the same vector. Moreover, booster immunizations are indispensable for the induction of long-term memory responses. 1 Despite this, here we demonstrate that prior injections with rSFV at dosages required for immune activation also reduce transgene expression of subsequently injected rSFV. Yet, in contrast to the almost complete inhibition observed with rAd, preinjection with rSFV results in a 1-to 2-log decrease. Currently, we are further investigating the mechanisms and kinetics of anti-vector responses in rSFV immunizations.
It is known that the mechanism of the activation of an immune response by these vectors differs. Our own studies strongly suggest that the immune response evoked by SFV immunizations does not occur via direct priming of DCs but via cross-presentation of antigen by DCs that have taken up apoptotic rSFV-transfected cells. 30 Recently, Chen et al. 31 confirmed that infection of DCs with rSFV in vitro indeed is very inefficient, and provided further proof that cross-priming is the main mechanism by which immunity to a rSFV is generated. An other important feature of rSFV is that infection of cells with SFV results in the formation of doublestranded RNA intermediates that are known for their immunopotentiating capacity. 32, 33 Mercier et al. 34 compared the immune response induced by an i.m. injection of rAd alone with that induced by cells transduced ex vivo with the rAd. They demonstrated that in muscle, Ad-transduced myoblasts and endothelial cells are very poor inducers of antigen-specific CD8 + T-cell response either by direct stimulation or by cross-priming, and that transduction of DCs is essential for induction of a CD8 + T-cell response. Yet, DCs do not express the primary Ad receptor, coxsackie-Ad receptor. As a consequence Admediated transduction of DCs is inefficient. 35 Furthermore, Rea et al. 36 showed that DCs activated in vitro by rAd lack a high level of CD83 expression and IL-12 production, and therefore, are inhibited to fully mature and polarize towards a Th1-inducing phenotype. This may explain why higher doses of rAd5 compared to rSFV are needed to elicit effective immune responses. Recently, De Gruijl et al. 37 demonstrated that the rAd35 vector, which uses CD46 as a high-affinity receptor which is expressed on human DCs, does infect migrated and mature CD83 + cutaneous DCs with high efficiency when delivered intradermally in an established human skin explant model. They furthermore demonstrated that upon intracutaneous delivery of a rAd35 vaccine, emigrated DC functionally express and process encoded antigenic epitopes and were capable of activating specific CD8 + effector T cells.
Apart from differences in the activation pathway leading to an immune response, the induction of memory T cells generated upon immunization with both vectors might also explain the differences in efficacy of immunization with rAd compared to rSFV. Immunization with viral vector may generate effector T cells against the encoded antigen. Differentiation of these effector T cells into memory T cells follows a linear pathway. 38 As mentioned above, we showed that for SFV-eE6,7 immunizations, boosting with SFV-eE6,7 is required for the induction of CTL memory, resulting in high levels of CTL activity up to 12 months after immunization.
1,2 A single immunization results in a rapid decrease in CTL activity within weeks after the immunization. 1 Following immunization with rAd, one can envision two possible mechanisms by which this differentiation pathway into memory T cells could be disturbed. First, the strong anti-vector response induced after immunization with rAd prohibits the effect of boosting, and hence a good CTL memory. Second, the prolonged expression of antigen with rAd results in effector T cells, which fail to acquire the key properties of memory cells. These effector T cells are maintained for some time and mediate immediate (partial) protection from a challenge. However, no functional central memory T cells are generated. As a consequence, upon antigen removal, effector T cells disappear and memory T cells do not develop. 39 The balance between too little, just right and too much stimulation determines the induction of memory T cells that acquire memory traits, including the ability to undergo homeostatic proliferation, rapid proliferation upon secondary challenge and the ability to produce cytokine. 40 Our studies suggest that the SFV vector system possesses the ability to generate the 'just right' level of stimulation.
In this study, we only evaluated immune responses against E7 although the vaccines encode both E6 and E7. In a separate study, we demonstrated that in patients with cervical cancer or premalignant cervical lesions E6 and E7 responses are present. 41 We recently demonstrated that these responses in patients are largely inhibited by the presence of regulatory T cells. After in vitro depletion of regulatory T cells, PBMC readily respond (interferon-g release) to both E6 and E7 protein in 60-80% of the patients. 42 In conclusion, the SFV vector system proved significantly more immunostimulating than the adenoviral type 5 vector system. As, immunization with SFV-eE6,7 resulted not only in twofold higher pCTL frequencies and significantly higher levels of CTL activity, also a significantly superior therapeutic effect was seen after SFV-eE6,7 immunization requiring 100-to 1000-fold lower doses compared to Ad-eE6,7 immunization. Together with the high level of biosafety of the SFV vector system and the absence of pre-existing neutralizing antibodies in humans, it seems worthwhile to tackle the severe regulatory hurdles that have to be taken for the evaluation of this 'novel' vector system in humans.
Materials and methods

Cell lines
Baby hamster kidney cells (BHK-21) were obtained from the American Type Culture Collection (Manassa, VA, Immunotherapeutic efficacy of recombinant SFV and adenovirus vector systems A Riezebos-Brilman et al USA; no. CCL-10). The cells were grown in GMEM (Invitrogen, Breda, The Netherlands) containing 5% fetal calf serum. C3 cells, 13-2 cells and TC-1 cells were kindly provided by Dr C Melief and Dr R Offringa (Leiden University, Leiden, The Netherlands). The C3 cell line was derived from C57Bl/6 (H-2 b ) embryonic cells transfected with a plasmid containing the complete HPV16 genome. 43 The 13-2 cell line was generated from C57Bl/6 (H-2 b ) embryonic cells transfected with the E1 region of Ad type 5 in which the adenoviral E1A epitope SGPSNTPPEI is replaced by a HPV16 E7 CTL epitope, AA 49-57 (RAHYNIVTF). 44 The TC-1 cell line was generated from C57Bl/6 primary lung epithelial cells with a retroviral vector expressing HPV16 E6E7 plus a retrovirus expressing activated c-Ha-ras.
45 C3, 13-2 and TC-1 cells were grown in IMDM with Glutamax-I (Invitrogen) supplemented with 10% fetal calf serum and penicillin and streptomycin (Invitrogen; 100 U ml À1 and 100 mg ml À1 , respectively). TC-1 medium was furthermore supplemented with non-essential amino acids (Invitrogen; 100-fold dilution), sodium pyruvate (Invitrogen, Paisley, UK; 1 mM) and Geneticin G418 Sulphate (Roche, Vienna, Austria; 5 mg ml
À1
).
Mice
Specific pathogen-free female C57Bl/6 mice (Harlan CPB, Zeist, The Netherlands) were between 6 and 10 weeks of age at the start of the immunization protocols.
Production, purification and titre determination of rSFV
The production, purification and titer determination of recombinant SFV-eE6,7, SFV-lacZ and SFV-luc was performed as described previously. 1 In short, pSFV3-eE6,7, pSFV3-lacZ and pSFV3-luciferase were produced using pSFV-Helper 2 and quantified using BHK-21 cells. pSFV3-eE6,7 encodes an enhanced expression of a fusion product of E6 and E7 of HPV type 16.
Production of rAd5
All recombinant vectors were constructed through homologous recombination in Escherichia Coli using the AdEasy system. 44 The E6,7 fusion protein was isolated from the pHelix eE6,E7 plasmid 1 using restriction enzymes XbaI and KpnI and cloned into the AdTrackCMV plasmid using the same enzymes. This resulted in expression of E6,7 under control of the cytamegalovirus (CMV) promoter. The recombinant E1 and E3 deleted vector was grown on 293 cells and purified in HEPES/sucrose buffer, pH 8.0, according to conventional double CsCl gradient centrifugation method. The number of viral particles was calculated from the optical density at 260 nm (OD 260 ). 46 Infectious units were determined by limiting dilution assay. In short, 293 human embryonic kidney cells were plated at 10 000 cells per well in a 96-well plate. Next day, 100 ml of 10-fold dilutions of the sampled media were added to the wells in 5-or 10-fold. Cytopathic effect was monitored every 2-3 days and scored at day 14. Plaque-forming units were calculated according to standard procedures. This vector contains green fluorescent protein (GFP) as reporter genes under control of CMV promoter. 47 Initial experiments were performed using an adenovirus with two expression cassettes (CMV-GFP and CMV-luc; AdGFP-luc). 48 
Immunizations
For CTL analysis, mice were immunized with either varying doses of infectious particles of SFV-eE6,7 intravenously or intramuscularly or with Ad-eE6,7 intramuscularly, intraperitoneally or subcutaneously, followed by one booster immunization with a 2-week interval. As negative controls, mice were injected with dialysis buffer, PBS or Ad-luc.
CTL assay
Seven to ten days after immunization, spleen cells were isolated and co-cultured with irradiated (100 Gy) TC-1 cells in a ratio of 25 Cr release was always o15%. The standard errors of the means of the triplicate determinations were o10% of the mean. Similar levels of specific lysis were obtained using C3 or 13-2 cells; only the results obtained with the C3 cells are shown.
MHC class I tetramer staining and FACS analysis
To analyse the number of CD8 + T cells specific to the HPV 16 E7 49-57 peptide RAHYNIVTF, we used K 
Luciferase assay
To determine luciferase activity, organs were collected, immediately frozen in liquid nitrogen and kept at À801C. Organs were crunched into powder in a mortar on dry ice. For luciferase determination, the Luciferase Reporter 1000 Assay System (Promega, Leiden, The Netherlands; cat. no. E4550) was used. Firefly luciferase, a monomeric 61 kDa protein, catalyses luciferin oxidation using ATP-Mg 2+ as a cosubstrate. In the conventional assay for luciferase, a flash of light is generated that decays rapidly after the enzyme and substrates are combined. The Luciferase Assay System incorporates coenzyme A for improved kinetics, allowing greater enzymatic turnover resulting in increased light intensity that is nearly constant for at least 1 min. In brief, the material was lysed in lysis buffer (Promega) (300 ml per 0.1 g of tissue). The suspension was frozen and thawed three times with vigorous vortexing in between. To remove cell debris, the suspensions were centrifuged twice in an Eppendorf centrifuge. Immediately before measurement, 4 ml of the supernatant of the samples was mixed with
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Tumour treatment experiments
Mice were inoculated subcutaneously in the neck with 2 Â 10 4 TC-1 cells suspended in 0.2 ml Hank's Buffered Salt Solution (Invitrogen). Subsequently, mice were immunized and boosted twice with a 1-week interval, with SFV-eE6,7, Ad-eE6,7, Ad-luc or dialyse buffer starting at days 7 or 14 after tumour inoculation. Immunization routes were i.v. for SFV-eE6,7 and i.m. for Ad-eE6,7, Ad-luc and dialyse buffer. The same skilled technician always did tumour measurements. At a tumour volume of approximately 1000 mm 3 , the mice were killed.
In vivo depletion of T-cell subsets and tumour challenge
For the in vivo depletion of CD4 + and CD8 + T cells, the mAbs GK1.5 (anti-CD4) and 2.43 (anti-CD8) were used. The hybridomas were kindly provided by Professor A Kruisbeek. (Free University Amsterdam, The Netherlands). The mAbs were produced by culturing the hybridoma cells in the two-chamber cell culture device CELLine 350 (Integra Biosciences, Chur, Switzerland) according to the manufacturer's instruction. For the purification of the mAbs, HiTrap Protein G HP 1 ml columns (Amersham Biosciences, Diegem, Belgium) were used in a fast protein liquid chromatography system. mAb concentrations were determined by spectrophotometry at 280 nm using an extinction coefficient of 1.35 mg ml
À1
. The in vivo depletion was performed by i.p. injection of 200 mg per mouse of anti-CD4, anti-CD8 or both for three consecutive days followed by a weekly injection. Depletion of lymphocyte subsets was assessed by flow cytometric analysis of spleen cells using anti-CD4-PE (IQ Products, Groningen, The Netherlands/Pharmingen) and anti-CD8-FITC (Pharmingen) antibodies. This antibody treatment resulted in 97% depletion of CD8 T cells and 91% depletion of CD4 T cells in spleen. In blood, 95 and 83% depletion of CD8 and CD4 T cells, respectively, was obtained with this treatment (data not shown). This level of depletion was maintained by the weekly injections.
For the tumour challenge experiment, mice were immunized and boosted with 5 Â 10 6 SFV-eE6,7 intravenously or 5 Â 10 8 Ad-eE6,7 intramuscularly. Six days after the booster injection and 6 days before tumour inoculation in vivo antibody depletion was initiated. One week after the initiation of the depletion, the mice were challenged subcutaneously with 2 Â 10 4 TC-1 cells suspended in 0.2 ml Hank's Buffered Salt Solution (Invitrogen).
Statistical analysis
Data depicted in Figure 4 were statistically analysed using w 2 testing. The other data with the Mann-Whitney U-test.
